Treatment of low-risk myelodysplastic syndromes

Although neutropenia is targeted symptomatically with growth factor supportive care, the immunosuppressive therapy is indicated mainly for pancytopenic and hypoplastic low-risk MDS, but it should be carefully evaluated to balancing toxicity and the possibility of survival advantage.